HAEM5:Lymphoplasmacytic lymphoma - Revision history

Bailey.Glen at 17:20, 3 July 2025

2025-07-03T17:20:19Z

← Older revision		Revision as of 12:20, 3 July 2025
Line 39:		Line 39:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:39, 25 May 2025

2025-05-25T21:39:48Z

← Older revision		Revision as of 16:39, 25 May 2025
Line 153:		Line 153:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 236:		Line 236:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 289:		Line 289:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 335:		Line 335:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:16, 25 May 2025

2025-05-25T20:16:07Z

← Older revision		Revision as of 15:16, 25 May 2025
Line 54:		Line 54:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:39, 24 March 2025

2025-03-24T17:39:43Z

← Older revision		Revision as of 12:39, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Lymphoplasmacytic lymphoma}}		{{DISPLAYTITLE:Lymphoplasmacytic lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 18:		Line 17:

	Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)		Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-13T22:15:09Z

Gene Mutations (SNV/INDEL)

← Older revision		Revision as of 17:15, 13 February 2025
Line 290:		Line 290:

	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV/INDEL)==
			Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span>
			{\| class="wikitable sortable"
			\|-
			!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
			'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
			!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T '''
			!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
			!'''Clinical Relevance Details/Other Notes'''
			\|-
			\|<span class="blue-text">EXAMPLE:</span>''EGFR''

			<br />
			\|<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations
			\|<span class="blue-text">EXAMPLE:</span> Oncogene
			\|<span class="blue-text">EXAMPLE:</span> Common (lung cancer)
			\|<span class="blue-text">EXAMPLE:</span> T
			\|<span class="blue-text">EXAMPLE:</span> Yes (NCCN)
			\|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references).
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
			<br />
			\|<span class="blue-text">EXAMPLE:</span> Variable LOF mutations
			\|<span class="blue-text">EXAMPLE:</span> Tumor Supressor Gene
			\|<span class="blue-text">EXAMPLE:</span> Common (breast cancer)
			\|<span class="blue-text">EXAMPLE:</span> P
			\|
			\|<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer.
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
			\|<span class="blue-text">EXAMPLE:</span> Activating mutations
			\|<span class="blue-text">EXAMPLE:</span> Oncogene
			\|<span class="blue-text">EXAMPLE:</span> Common (melanoma)
			\|<span class="blue-text">EXAMPLE:</span> T
			\|
			\|
			\|-
			\|
			\|
			\|
			\|
			\|
			\|
			\|
			\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

	<br />		<br />

Bailey.Glen: /* Characteristic Chromosomal or Other Global Mutational Patterns */

2025-02-13T22:14:27Z

Characteristic Chromosomal or Other Global Mutational Patterns

@@ Line 235: / Line 235: @@
 ==Characteristic Chromosomal or Other Global Mutational Patterns==
 Put your text here
@@ Line 254: / Line 288: @@
+|
 |}
 ==Gene Mutations (SNV/INDEL)==

Bailey.Glen: /* Individual Region Genomic Gain/Loss/LOH */

2025-02-13T22:13:54Z

Individual Region Genomic Gain/Loss/LOH

@@ Line 154: / Line 154: @@
 ==Individual Region Genomic Gain/Loss/LOH==
 {| class="wikitable sortable"
@@ Line 181: / Line 233: @@
+|
 |}
 ==Characteristic Chromosomal or Other Global Mutational Patterns==

Bailey.Glen: /* Gene Rearrangements */

2025-02-13T22:13:20Z

Gene Rearrangements

@@ Line 69: / Line 69: @@
 ==Gene Rearrangements==
@@ Line 93: / Line 152: @@
 ----
 </blockquote>
 ==Individual Region Genomic Gain/Loss/LOH==

Bailey.Glen: Removed old template contents

2025-02-11T16:57:40Z

Removed old template contents

Show changes

Bailey.Glen at 18:51, 10 February 2025

2025-02-10T18:51:16Z

← Older revision		Revision as of 13:51, 10 February 2025
Line 10:		Line 10:
	}}</blockquote>		}}</blockquote>

	<span style="color:#0070C0">(General Instructions – The ~~main~~ focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears ~~to be given options~~. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>		<span style="color:#0070C0">(General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)</span>

	==Primary Author(s)*==		==Primary Author(s)*==
Line 177:		Line 177:
	----		----
	</blockquote>		</blockquote>
	==~~Chromosomal Rearrangements~~ (Gene ~~Fusions)~~==		==WHO Essential and Desirable Genetic Diagnostic Criteria==
			<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
			{\| class="wikitable"
			\|+
			\|WHO Essential Criteria (Genetics)*
			\|
			\|-
			\|WHO Desirable Criteria (Genetics)*
			\|
			\|-
			\|Other Classification
			\|
			\|}
			<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
			==Related Terminology==
			<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
			{\| class="wikitable"
			\|+
			\|Acceptable
			\|
			\|-
			\|Not Recommended
			\|
			\|}

			==Gene Rearrangements==


Line 202:		Line 227:
	----		----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain/Loss/LOH==

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 230:		Line 255:
	\|		\|
	\|}		\|}
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal or Other Global Mutational Patterns==

	Put your text here		Put your text here
Line 250:		Line 275:
	\|		\|
	\|}		\|}
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV/INDEL)==

	<br />		<br />
Line 308:		Line 333:

	==Epigenomic Alterations==		==Epigenomic Alterations==


	Put your text here		Put your text here

	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==

Line 332:		Line 357:
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

	~~Put your text here~~

			Put your text here <span style="color:#0070C0">(''Instructions: Include recommended testing type(s) to identify the clinically significant genetic alterations.'')</span>
	==Familial Forms==		==Familial Forms==


	Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>		Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>

	==Additional Information==		==Additional Information==

Line 344:		Line 369:
	==Links==		==Links==

	Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page <span style="color:#0070C0">(''Instructions: Highlight text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>

			Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>
	==References==		==References==
	<references />		<references />